darifenacin


Also found in: Medical, Wikipedia.
Related to darifenacin: Tolterodine, darifenacin hydrobromide
Translations

darifenacin

n darifenacina
References in periodicals archive ?
4) Several approved medications are used in management of OAB in Canada including: oxybutynin chloride, tolterodine tartrate, trospium chloride, solifenacin succinate, darifenacin hydrobromide, and fesoterodine fumarate.
Furthermore, new-generation anticholinergic agents, such as darifenacin and solifenacin, are selective for the M3 receptor and thus offer the potential of reduced side-effects.
Available agents include darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, and trospium.
Urinary tract drugs: Darifenacin, Fesoterodine, Solifenacin, Silodosin, Tamsulosin
Antimuscarinics, such as oxybutynin, tolterodine, darifenacin, solifenacin, fesoterodin, and trospium chloride are the only oral drug class to demonstrate a positive benefit-to-risk ratio.
There are seven anticholinergics that are used as antispasmodics for the treatment of overactive bladder: darifenacin (Enablex) [C], fesoterodine (Toviaz) [C], flavoxate (Urispas) [B], oxybutynin (Ditropan) [B], solifenacin (Vesicare) [C], tolterodine (Detrol) [C], and trospium (Sanctura) [C].
In 2004, the FDA approved the three newest agents for the class: darifenacin, solifenacin, and trospium.
Pharmacotherapy (anticholinergic medication) includes any form of oxybutynin, tolterodine, trospium chloride, solfenacin, or darifenacin.
To date, 97 clinical trials with Emselex have been carried out involving more than 10,500 subjects and patients, of whom 7,146 were treated with darifenacin.
3] Seven different anticholinergics are currently marketed for the treatment of DO/NDO in adults (oxybutynin, tolterodine, trospium, darifenacin, solifenacin, propiverine and fesoterodine), but none of them has been shown superior to another.
Darifenacin, a selective muscarinic M3 receptor antagonist approved last month for the treatment of overactive bladder, doesn't affect cognition in the elderly at clinically effective doses, Richard B.